Efficacy and safety of gabapentin versus placebo to prevent the incidence of PostHerpetic Neuralgia

Gerencia de Atención Primaria de Mallorca0 个研究点开始时间: 2013年10月22日最近更新: 2017年6月5日

适应症

试验速览

暂无简介。

•Patient aged >= 50 , diagnosed by uncomplicated herpes zoster with a < de 72h onset.
•Visual analog scale of pain ? 4 (rated 0 to 10).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 54
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 80

•Current or anticipated treatment with gabapentine or triciclys antidepresants
•Patients diagnosed of hepatic insufficiency
•Patients with a a history of intolerance of hipersensitivity to gabapentin or excipients.
•Patients with impaired renal function (Clcr <79ml/min)
•Patients with evidence of cutaneous, ocular or visceral disemination of herpes zoster infection (cutaneous disemination is defined as > 20 discrete lesion outside adjacent dermatomes) evidencia de diseminación cutánea o visceral del HZ (más de 20 lesiones fuera del
•dermatoma adyacente)
•Patients who have received inmunosupresive therapy in the last 3 months or inmunomodulatory medication (including interferon) within the previous 4 weeks
•Patient diagnosed of inmunodeficiency

发起方

Gerencia de Atención Primaria de Mallorca